Navigation Links
Galderma Launches New Cetaphil(R) SPF 50 Product
Date:2/17/2009

Top Skin Care Brand is Taking Facial Sun Protection to a New Level

FORT WORTH, Texas, Feb. 17 /PRNewswire/ -- Galderma Laboratories is excited to introduce a NEW SPF 50 facial moisturizer from Cetaphil(R), the #1 dermatologist-recommended brand of cleansers and moisturizers, that provides broad spectrum protection. Finally, a product that goes beyond moisturizing, to provide the highest SPF available for a moisturizer designed specifically for the face. Cetaphil(R) UVA/UVB Defense SPF 50 is non-greasy; it nourishes and hydrates skin, while protecting it from the sun's harmful rays.

Cetaphil(R) UVA/UVB Defense SPF 50 delivers across the spectrum to help protect skin from UVA/UVB rays, and help hydrate as a daily facial moisturizer. It contains an optimum blend of 4 filters and micronized Titanium Dioxide that screen both the UVA and UVB rays. For patients requiring an effective sunscreen as part of the management of their skin related condition, Cetaphil(R) UVA/UVB Defense SPF 50 combines two steps in one making it an ideal choice for both daily sun protection and for moisturizing the face.

Cetaphil(R) UVA/UVB Defense SPF 50 has also been awarded the Skin Cancer Foundation Seal of Recommendation. The Skin Cancer Foundation recommends this product as an effective UV facial sunscreen and as an effective aid in the prevention of sun induced damage to the skin including sunburn and possibly, premature aging. It is important to use proper UVA/UVB filters to help prevent sunburn and other skin damage.

The lightweight formula of the Cetaphil(R) UVA/UVB Defense SPF 50 hydrates the skin to avoid evaporation and absorbs quickly, leaving no filmy white residue. It is fragrance free, non-irritating and non-comedogenic, so it won't clog pores, making it a suitable choice for those with acne, rosacea or melasma and other skin related conditions, where a hydrating formula with SPF protection is recommended.

Cetaphil(R) UVA/UVB Defense SPF 50 is available in a 1.7 oz. tube for $13.99 and is available at major retail, grocery and drug stores nationwide.

For more information about Cetaphil(R) products or to join the Cetaphil(R) Skin Care Club, visit www.cetaphil.com.

About Galderma

Galderma, created in 1981 as a joint venture between Nestle and L'Oreal, is a fully-integrated specialty pharmaceutical company dedicated exclusively to the field of dermatology. The Company is committed to improving the health of skin with an extensive line of products across the world that treat a range of dermatological conditions. With a research and development center in Sophia Antipolis, France, Galderma has one of the largest R&D facilities dedicated exclusively to dermatology. Leading worldwide dermatology brands include Differin(R), MetroGel(R) 1%/Rozex(R), Clobex(R), Tri-Luma(R), Loceryl(R) and Cetaphil(R).

For more information on Galderma, visit www.galdermaUSA.com.

About Cetaphil

The Family of Cetaphil(R) Cleansers and Moisturizers is a line of dermatologist-recommended skin care products specially formulated for all skin types and conditions. Cetaphil(R) products are developed to provide effective, gentle skin care and include: Cetaphil(R) Gentle Skin Cleanser, Cetaphil(R) Daily Facial Cleanser, Cetaphil(R) Gentle Cleansing Bar, Cetaphil(R) Antibacterial Gentle Cleansing Bar, Cetaphil(R) Moisturizing Lotion, Cetaphil(R) Moisturizing Cream, Cetaphil(R) DailyAdvance Ultra Hydrating Lotion, Cetaphil(R) Daily Facial Moisturizer SPF 15, Cetaphil(R) Therapeutic Hand Cream.

To learn more about Cetaphil(R) products and to join the Cetaphil(R) Skin Care Club visit www.cetaphil.com


'/>"/>
SOURCE Galderma Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Galderma Wins FDA Approval for Vectical(TM) Ointment, a Novel Topical Therapy for Mild-to-Moderate Plaque Psoriasis
2. Galderma Announces Availability of Epiduo(TM) Gel, the First and Only Combination Treatment with a Retinoid and Benzoyl Peroxide to Treat Acne
3. Galderma announces approval for Differin gel 0.1 percent in Japan
4. Galderma Completes Tender Offer for CollaGenex
5. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
6. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
7. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
8. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
9. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
10. Crossover Health Launches Personal Health Advisory Service
11. Photos: Medpedia Launches
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/14/2016)... ... February 14, 2016 , ... ... of Heart Failure Nurses (AAHFN) is promoting healthier living with heart failure by ... of Life! Healthy Living with Heart Failure will kick-off February 14 and includes ...
(Date:2/13/2016)... ... February 13, 2016 , ... ... Voices of Recovery, the leading national organization representing the growing community of recovering ... public office to include Family Recovery in policies addressing addiction. , Although ...
(Date:2/13/2016)... ... February 13, 2016 , ... In ... states that vein visualization technology should be used to ensure patient safety when ... world, the INS Standards mandate the use of vein visualization technology in patients ...
(Date:2/13/2016)... ... , ... DDi , a Makro company, makes it ... expertise in eClinical Solutions. DDi has built its solution competency with a unique ... clients. DDi provides smarter technology for Clinical Development, Regulatory and Enterprise domains by ...
(Date:2/12/2016)... WA, and Washington, DC (PRWEB) , ... ... ... PATH and the Siemens Foundation today announced a new initiative—the Siemens Foundation-PATH ... for low-resource settings. The partnership will recruit top students from U.S. universities ...
Breaking Medicine News(10 mins):
(Date:2/12/2016)... Va. , Feb. 12, 2016   National ... Hoey , RPh, MBA issued the following statement today ... released by the Centers for Medicare & ... raised by NCPA, beneficiary advocates and others: ... raised. We are still reviewing the full CMS analysis. ...
(Date:2/12/2016)... , Feb. 12, 2016 Hypermarcas ... a cash tender offer (the "Tender Offer") to ... outstanding aggregate principal amount of its 6.500% Senior ... ISIN Nos. US44915JAA88/ USP5246AAF05) (the "Notes"). In connection ... (the "Consent Solicitation") consents (the "Consents") of the ...
(Date:2/12/2016)... -- Innophos Holdings, Inc. (NASDAQ: IPHS ), a leading international ... it will host a live conference call on Tuesday, February ... quarter and full year 2015 results. ... quarter and full year results will be issued on Monday, ... --> --> The conference call can be ...
Breaking Medicine Technology: